Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has called its first extraordinary general meeting of 2026 for 12 February in a hybrid format, combining a physical meeting in Beijing with an online e-meeting system to allow broader shareholder participation. Shareholders will vote on the proposed appointment of Mr. Liu Hongkang as a non-executive director, a move that could further shape the company’s board composition and corporate governance, with detailed procedures laid out for H shareholders and non-registered holders to attend, vote, and appoint proxies ahead of the meeting.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong (Stock Code: 2315), operating in the biotechnology and pharmaceutical industry with a focus on drug discovery and development. The company is governed by a board comprising executive, non-executive, independent non-executive and employee directors, reflecting a typical listed-company governance structure in the Hong Kong market.
Average Trading Volume: 1,465,713
Technical Sentiment Signal: Hold
Current Market Cap: HK$16.99B
See more data about 2315 stock on TipRanks’ Stock Analysis page.